Edward Roberts, PhD

Select Publications

• Guerrero, M.; Urbano, M.; Kim, E. K.; Gamo, A. M.; Riley, S.; Abgaryan, L.; Leaf, N.; Van Orden, L. J.; Brown, S. J.; Xie, J. Y.; Porreca, F.; Cameron, Michael D.; Rosen, Hugh; Roberts, Edward Design and synthesis of a novel and selective kappa opioid receptor (KOR) antagonist (BTRX-335140). Journal of Medicinal Chemistry 2019, 62, 1761-1780.

  View

• Xie, J. Y.; De Felice, M.; Kopruszinski, C. M.; Eyde, N.; LaVigne, J.; Remeniuk, B.; Hernandez, P.; Yue, X.; Goshima, N.; Ossipov, M.; King, T.; Streicher, J. M.; Navratilova, E.; Dodick, D.; Rosen, Hugh; Roberts, Edward; Porreca, F. Kappa opioid receptor antagonists: A possible new class of therapeutics for migraine prevention. Cephalalgia 2017, 37, 780-794.

  View

• Genetic and Pharmacologic Manipulation of TLR4 Has Minimal Impact on Ethanol Consumption in Rodents. The Journal of neuroscience : the official journal of the Society for Neuroscience 2017, 37, 1139-1155.

  View

• Burkert, K.; Zellmann, T.; Meier, R.; Kaiser, A.; Stichel, J.; Meiler, J.; Mittapalli, G. K.; Roberts, Edward; Beck-Sickinger, A. G. A deep hydrophobic binding cavity is the main interaction for different Y2R antagonists. ChemMedChem 2017, 12, 75-85.

  View

• Scott, F. L.; Clemons, B.; Brooks, J.; Brahmachary, E.; Powell, R.; Dedman, H.; Desale, H. G.; Timony, G. A.; Martinborough, E.; Rosen, Hugh; Roberts, Edward; Boehm, M. F.; Peach, R. J. Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P(1)) and receptor-5 (S1P(5)) agonist with autoimmune disease-modifying activity. British Journal of Pharmacology 2016, 173, 1778-1792.

  View

• Guerrero, M.; Urbano, M.; Roberts, Edward Sphingosine 1-phosphate receptor 1 agonists: a patent review (2013-2015). Expert Opinion on Therapeutic Patents 2016, 26, 455-470.

  View